Literature DB >> 17392609

Long QT syndrome under mitotane therapy.

R U Pliquett, U Eichfeld, M Stumvoll, C A Koch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17392609     DOI： 10.1007/BF03347417

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms.

Authors:  J B Lanser; A P van Seters; A J Moolenaar; H R Haak; E L Bollen
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544

Review 2.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

3.  Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors?

Authors:  C Pohlink; A Tannapfe; U Eichfeld; F Schmidt; D Führer; R Paschke; C A Koch
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 4.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

5.  Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane.

Authors:  I Ilias; M Alevizaki; G Philippou; E Anastasiou; A Souvatzoglou
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

6.  Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives.

Authors:  Prince J Kannankeril; Dan M Roden; Kris J Norris; S Patrick Whalen; Alfred L George; Katherine T Murray
Journal:  Heart Rhythm       Date:  2005-02       Impact factor: 6.343

7.  Toxicity, ultrastructural effects, and metabolic studies with 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane(o,p'-DDD) and its methyl analog in the guinea pig and rat.

Authors:  B L Jensen; M W Caldwell; L G French; D G Briggs
Journal:  Toxicol Appl Pharmacol       Date:  1987-01       Impact factor: 4.219

8.  Reversible mental deterioration and neurological disturbances with o,p'-DDD therapy.

Authors:  E Bollen; J B Lanser
Journal:  Clin Neurol Neurosurg       Date:  1992       Impact factor: 1.876
  8 in total
  1 in total

1.  No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma.

Authors:  S Ederhy; A Cohen; G Dufaitre; R Chaderevian; H Abbas; X Bertagna; R Libé
Journal:  J Endocrinol Invest       Date:  2012-09-24       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.